In conclusion, immune checkpoint inhibitors could be a recommendation for NSCLC patients having EGFR wild-type, KRAS mutation, and PD-L1 tumor proportion scores >1%. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.